Precision medicine specialist Natera has raised $250.0M, securing fresh capital to advance its work in genetic testing. The company, a global leader in cell-free DNA, is dedicated to making personalized diagnostics a standard part of care across oncology, women’s health, and organ health. Natera's tests are backed by more than 325 peer-reviewed publications, and it operates ISO 13485-certified and CAP-accredited laboratories in Austin, Texas, and San Carlos, California, with an additional facility in Boulder, Colorado, via its Foresight Diagnostics subsidiary.


















